The strong interaction between biotin and avidin is utilized for the development of enzyme-linked competitive binding assays not only for biotin itself, but also for other biomolecules. Alkaline phosphatase, a single substrate enzyme typically used for heterogeneous types of competitive binding assays, is employed also for homogeneous types. For the biotin assay, the heterogeneous protocol offers a much improved detection capability when compared to the homogeneous type. A simple approach of simulating dose-response curves is introduced. An effective analyte concentration attached to an enzyme label is determined by using the same binder, but with a different enzyme label. The analyte system adapted to the biotin/avidin-mediated homogeneous protocol is digoxin and a monoclonal anti-digoxin antibody. The detection capabilities of these assays, particularly the homogeneous types, are shown to be limited by the detectability of the enzyme conjugate employed.
Enzymes have emerged as the most powerful alternatives to radioisotopes in the development of binding assay methods for the selective detection of various physiological, biological and environmental substances at trace levels. [1] [2] [3] [4] Enzyme-linked competitive binding methods are based on a competition between the unlabeled analyte and an enzyme-analyte conjugate for a limited number of binding sites. Such methods can be classified as either heterogeneous (solid-phase) or homogeneous. The heterogeneous arrangements are time-consuming, but prevalent. The homogeneous types, such as the enzyme-multiplied immunoassay technique (EMIT) pioneered by Rubenstein et al. 3, 4 , are preferred because there is no need for time-consuming separation of free and bound enzyme-labeled analyte.
The strong and specific biotin/avidin interaction (K a =10 -15 M) has been used to develop EMIT-type homogeneous assays for biotin. 5, 6 Such a strong interaction between biotin and avidin may be utilized to detect other biomolecules rather than biotin. Recently, we have devised a generic-type homogeneous method by employing synthetic enzyme-biotin conjugates in conjunction with riboflavin and riboflavin binding protein as the model analyte and binding protein. 7 -9 In this method, the binding reaction between the enzymebiotin and avidin-analyte conjugates inactivates the enzyme. In the presence of analyte-specific binder, the enzymatic activity of the conjugate is regained since the binding of the binder to the avidin-analyte conjugate prevents the enzyme inactivation by sterically hindering the binding between the avidin-analyte and enzyme-biotin conjugates. When free analyte is added to the assay mixture, enzyme activity is re-inhibited in an amount proportional to the analyte concentration. We have examined three different enzymes as the labels in the development of such a biotin/avidin-mediated homogeneous method: glucose-6-phosphate dehydrogenase 7 (G6PDH), alkaline phosphatase 7, 8 (ALP) and adenosine deaminase. 7, 9 Factors that influence the analytical performance of the enzyme-linked competitive binding assays are manifold. 10 -12 However, the intrinsic detection capability of the binding assay system is dictated by the binding ability of the binder. For instance, biotin assays employing avidin as the binder must be able to achieve a very low detection limit (i.e., <10 -15 M) based on the known association constant of the biotin/avidin reaction. However, the detection limits of the homogeneous type biotin assays were found to be much higher (i.e., >10 -9 M), as reported previously with G6PDH 5 and adenosine deaminase 6 as the labeling enzymes. Such a poor detectability could also affect the performance of the biotin/avidin-mediated homogeneous assay system that employs the second analyte binder reaction: in this method, the enzyme-biotin conjugate acts as a signal generator and an avidin-analyte conjugate as a signal modulator. 7 -9 The aim of this work is to elucidate the factors that limit the detectability of the enzyme-linked competitive binding assays based on the biotin/avidin interaction. For this, both homogeneous and heterogeneous biotin assays are optimized, and their dose-response behaviors are compared with those predicted theoretically. In this work, we also examine the feasibility of adapting the biotin/avidin-mediated homogeneous assay method to a new analyte system by employing digoxin and a monoclonal anti-digoxin antibody. Finally, the analytical utility and limitations of the biotin/avidin-mediated assay protocol are discussed based upon the findings of this work.
Experimental

Reagents
ALP from bovine intestinal mucosa, d-biotin, ALPbiotinamidocaproyl labeled (ALP-amidocaproylbiotin), N-hydroxysuccinimidobiotin (NHS-biotin), pnitrophenyl phosphate, avidin from egg white, digoxin and bovine serum albumin (BSA) were obtained from Sigma (St. Louis, MO, USA). Monoclonal anti-digoxin antibody and avidin-digoxin conjugates were graciously provided by Dade Behring Inc. (Newark, DE, USA). All other chemicals used were of analytical-reagent grade.
The assay buffer was 0.05 M sodium carbonate (pH 9.5) containing 0.1 M NaCl, 0.01% NaN 3 , 0.01% gelatin and 0.2% BSA for homogeneous-type assays, and 0.05 M Tris-HCl (pH 7.8) containing 0.05% Tween 20, 0.02% NaN 3 and 0.5% BSA for heterogeneous assays. Dilutions of conjugates, binders, standards, and sample solutions were made using the assay buffer. The wash buffer used in the heterogeneous assay protocol was 0.05 M Tris-HCl (pH 7.8) containing 0.05% Tween 20 and 0.02% NaN 3 . Deionized water was used to prepare all buffers.
Enzyme-biotin conjugates
The ALP-biotin conjugates were synthesized using the N-hydroxysuccinimide ester method, as described previously. 7, 8 Briefly, the required amount of NHSbiotin dissolved in DMF (5 -50 mg/ml) was added to 500 µl of coupling buffer containing a given amount of ALP (183 units) dissolved in 0.05 M sodium carbonate, pH 9.5. The reaction was run for 24 h at 4˚C under stirring. The reaction mixture was then dialyzed against 0.05 M Tris-HCl, pH 7.4, and diluted to a final volume of 2.0 ml with the dialysis buffer. The resulting enzyme conjugates were characterized by their residual activities and percentages of inhibitions induced by an excess amount of avidin. [7] [8] [9] All conjugates were kept at 4˚C until the additions of reagents for activity measurements.
Homogeneous assays
The rate of appearance of p-nitrophenol, measured by the change in absorbance at 405 nm per unit time, was used to determine the activity of ALP-biotin conjugates. The assay involves addition of 100 µl of p-nitrophenyl phosphate (30 mM) to a tube containing 1100 µl of assay mixture described below. After mixing and agitation (1 -2 s) the reaction mixture was aspirated into a thermostated flow cell (at 30˚C) of a Gilford Spectrophotometer (Stasar III; Syva, Palo Alto, CA, USA) connected to an EMIT Clinical Processor (CP-5000; Syva, Palo Alto, CA, USA). The absorbance of the mixture in each tube was read over a 1-min period (∆ A/min) after an initial 20-s delay. For homogeneous biotin assays, 100 µl of the biotin standards were added to an assay tube containing 100 µl of an avidin solution and 800 µl of assay buffer. After incubation for 5 min, 100 µl of an ALP conjugate was added, and the mixture was incubated for a further 10-min period prior to activity measurements as outlined above.
In the biotin/avidin-mediated assay protocol for digoxin, 100 µl of the digoxin standards were added to an assay tube containing 100 µl of an anti-digoxin solution and 700 µl of assay buffer. After incubation for 5 min, 100 µl of an avidin-digoxin conjugate was added, and the mixture was incubated for a further 10-min period. A volume of 100 µl of an ALP-biotin conjugate solution was then added, and the mixture was incubated for 10 min prior to activity measurements as described above. Dose-response curves were constructed by plotting absorbance change (∆ A/min) vs. logarithm of the analyte (biotin or digoxin) concentration in the standards.
Heterogeneous assays
Heterogeneous biotin assays were performed by first immobilizing avidin on the inner surface of microwells by physical adsorption. For this, each well of a polystyrene-based plate (Falcon 3912; Becton Dickinson, Oxnard, CA, USA) was filled with 100 µl of an avidin solution in 0.05 M sodium bicarbonate (pH 9.6), and incubated for 16 h at 4˚C. After being washed twice with wash buffer, the microwells were filled with 200 µl of 1% BSA in wash buffer, and incubated for 1 h at room temperature.
For biotin dose-response curves, 100 µl of the biotin standards were added to each avidin-coated well, and incubated for 1 h. After washing, 100 µl of an ALPamidocaproyl-biotin conjugate solution was added to each well, and incubated for 1 h. The wells were then washed and filled with 100 µl of 10 mM p-nitrophenyl phosphate dissolved in 1.0 M diethanolamine (pH 9.8) containing 0.5 mM magnesium chloride. After incubation for 30 min at room temperature, the absorbance of the wells was determined with an Emax precision microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 405 nm.
Results and Discussion
Homogeneous-type assays rely on the ability of analyte-specific binders to inhibit the catalytic activity of enzyme conjugated with analyte. Therefore, their 344 ANALYTICAL SCIENCES APRIL 1999, VOL. 15
analytical performance depends heavily on the characteristics of the enzyme conjugate employed. The catalytic activity of the enzyme-analyte conjugate employed in this type needs to be inhibited substantially when the conjugate is bound by the analyte-specific binder. For this an ALP-biotin conjugate was prepared by employing a relatively high initial molar NHSbiotin/ALP ratio (i.e., 2250) during the conjugation reaction. This particular conjugate, which possesses a residual activity of 44% and is inhibited up to 90% by an excess of avidin, was used in all subsequent homogeneous type assays.
In Fig. 1 , five different dose-response curves for biotin were constructed by varying the amounts of both ALP-biotin and avidin in the assay mixture: A) 0.60 units and 10.0 µg, B) 0.36 units and 3.33 µg, C) 0.18 units and 1.25 µg, D) 0.36 units and 0.40 µg, and E) 0.60 units and 0.33 µg. As can be seen, all of the curves are relatively steep over a narrow concentration range as is typical with enzyme-linked competitive assays using binding proteins as the binders. As expected, decreasing the amounts of both reagents shifted the dose-response curve to a lower detection range, and decreased the enzymatic analytical signal (compare curves A, B and C). Further decreasing the reagent concentrations is possible for an improvement of detection limit, but this will also reduce the analytical signal to an unacceptable level in the homogeneous assay protocol employed in this study.
The dose response behavior of the competitive binding assay is also affected by the ratio of binder/enzyme conjugate employed in the assay mixture, as demonstrated both theoretically 10 and experimentally. 11, 12 In the present work, three different ratios of the ALPbiotin and avidin concentrations were selected; these yield a similar extent of analytical signal for each dose-response curve (i.e., curves C, D and E in Fig. 1 ). As can be seen, increasing the amount of ALP-biotin while decreasing the amount of avidin results in a curve with a lower detection capability. However, this comes at the expense of an increase in the signal-to-noise ratio (S/N) caused by an increased level of the background enzymatic signal. Furthermore, with the increased use of ALP conjugate in the assay mixture, the enzymatic signal will approach rapidly to the upper limit of absorbance range of the spectrophotometer.
The detection limit (>10 -8 M biotin) achieved with the present ALP-based assay is not very different from those observed previously with the homogeneous biotin assays using G6PDH 5 and adenosine deaminase 6 as the labeling enzymes. In principle, the intrinsic detection limit of the binding assay is determined mainly by the binding ability of the binder system. In the case of the biotin assay with avidin as the binder, a limit of detection lower than 10 -15 M biotin is possible based on the known association constant of the biotin/avidin reaction (K a =10 -15 M).
In an effort to explain such a poor detection capability observed with the present ALP-based homogeneous assay system, dose-response curves were simulated by the following equilibrium expressions:
where P is the unlabled analyte (biotin), P* is the labeled analyte (ALP-biotin), and Q is the binder (avidin). K and K* are the association constants for the two reactions. The association constant of biotin toward avidin (i.e., K ) is known to be 1.0×10 15 M -1 . The association constant of the ALP-labeled biotin toward avidin (K*) could be estimated if the average number of biotin molecules attached to an ALP label is determined. In this work, however, a new approach of simulating the dose-response curve of the enzymelinked binding assay was attempted. In this approach, the concentration of the labeled biotin is estimated as the concentration of the unlabeled biotin. This can be done by employing a biotin assay using an enzyme label different from ALP. In the present example, a G6PDH-based homogeneous biotin assay 5,7 was employed to determine the effective biotin concentration attached to ALP in the conjugate solution: an average number of 10.1 biotin molecules per ALP molecule was calculated for the ALP-biotin used in the assay. In this approximation, K* is equal to K since the concentration of the labeled biotin [P*] is expressed as that of the unlabeled biotin [P] .
With the assumptions made above (i.e., K=K*=1.0×10 -8 M for both reagents, and E) 7.1×10 -8 M and 7.1×10 -9 M. It can be seen, indeed, that detection ranges of the theoretical dose-response curves are not very different from those observed with the experimental curves (compare curves A -C in Fig. 2 with curves C -E in Fig. 1 ). It should be also noted that an experimentally optimized curve (C) for the ALP-based homogeneous assay employs a reagent ratio near [P*]/[Q]=1: it is well known that the lowest detection is possible at an equal concentration of the labeled analyte and binding site (i.e., initial [P*]/[Q]=1) in the case of K=K*, as depicted in Fig. 2 .
On the basis of such theoretical treatments, it is necessary to reduce the amounts of both reagents (i.e., ALP-biotin and avidin) to lower the detection limit of the ALP-based biotin assay further. This was demonstrated by performing a heterogeneous type biotin assay as shown in Fig. 3 . In this method, enzyme activities bound to a solid phase are measured. Thus, a less substituted conjugate is typically preferred for a greater enzymatic signal: a commercial ALP-amidocaproylbiotin conjugate with 3 -6 biotin molecules per protein molecule was employed for the present heterogeneous assay. As can be seen in Fig. 3 , the heterogeneous method achieved a much improved detection limit (i.e., near 10 -13 M biotin) when compared to the homogeneous method. This was expected based on much lower reagent concentrations used in the heterogeneous assay protocol: with a fixed amount of ALP-amidocaproyl-biotin (0.04 units or 1.5×10 -9 M of unlabeled biotin), the amount of avidin for each curve is A) 0.2 µg, B) 0.1 µg and C) 0.013 µg. Again, decreasing the binder concentration shifted the dose-response curve to a lower detection range. However, this occurred at the expense of decreasing the extent of the analytical signal (i.e., maximum percent inhibition) of the curve (not shown). In an optimized assay protocol, the enzymatic activity should be easily monitored within a reasonably short measuring period. Therefore, in order to lower the detection limit of the biotin assay to a level of its intrinsic detectability (i.e., near 10 -15 M), it is required to employ an enzyme label or other tracers for which more sensitive detection techniques are available (e.g., fluorescence).
We have previously shown that the strong interaction between biotin and avidin can be used to develop homogeneous type assays for biomolecules other than biotin by employing riboflavin and riboflavin binding protein as the model analyte and binding protein. [7] [8] [9] In the present work, a different analyte system (i.e., digoxin/anti-digoxin antibody) was examined in an effort to demonstrate the utility of such a biotin/avidinmediated protocol as a generic approach of developing homogeneous type assays. Digoxin is commonly used as a cardioactive drug, and its therapeutic levels in serum range from 0.8 to 2.0 ng/ml. 13 In the present homogeneous digoxin assay, we employed an avidindigoxin conjugate with an average number of 30 digoxin molecules per avidin molecule, and an antidigoxin mouse monoclonal antibody with an association constant of about 4×10 11 M -1 . The enzyme activity was inactivated up to 85% by the binding reaction 346 ANALYTICAL SCIENCES APRIL 1999, VOL. 15 between the ALP-biotin and the avidin-digoxin conjugates. In the presence of anti-digoxin antibody, the enzyme activity was improved up to 68%: i.e., the binding of the antibody to the avidin-digoxin conjugate prevents the enzyme inactivation. Figure 4 illustrates a dose-response curve obtained with a biotin/avidinmediated homogeneous assay for digoxin, optimized in this work. A relatively steep dose-response behavior observed over a narrow concentration range (i.e., 10 -6 to 10 -7 M) indicates that the assay can be used for the precise determination of analyte. However, the detection limit achieved with the present homogeneous assay is not adequate if used for serum digoxin measurements (i.e., (1.0 to 2.5)×10 -9 M). The performance of the biotin/avidin-mediated assay system is influenced by two different binding reactions: biotin/avidin and target analyte/binder reactions. In principle, the intrinsic detection capability of the final assay is determined by the weaker binder reaction. However, the poor detectability (>10 -7 M) observed with the present digoxin assay is attributed to a very high reagent concentration used in the assay considering the association constant of digoxin toward its antibody (K a =4×10 -11 M). Therefore, a more sensitive detection scheme for the labeled biotin is needed to develop a clinically relevant homogeneous assay for digoxin.
In conclusion, the strong biotin/avidin interaction has proven useful once again in the development of enzyme-linked competitive binding assays not only for biotin itself but also for other biomolecules such as digoxin. The detection capabilities of these assays, particularly the homogeneous types, are limited by the detectability of the enzyme conjugate employed. With a careful selection of the analyte and sample matrix system, however, the biotin/avidin-mediated approach could offer a rapid alternative for the measurement of a variety of biomolecules.
